Quality Control in Huntington's Disease: a Therapeutic Target

Area of Science:

• Neuroscience
• Genetics
• Cell Biology

Background:

• Huntington's disease (HD) is an inherited neurodegenerative disorder caused by expanded CAG repeats in the huntingtin gene.
• This leads to toxic huntingtin protein aggregates, disrupting cellular quality control and causing neuronal death.
• Current treatments focus on symptom management, as the causative agent for increased neuronal vulnerability remains unclear.

Purpose of the Study:

• To review therapeutic strategies targeting protein quality control mechanisms in Huntington's disease.
• To explore approaches aimed at enhancing the clearance of toxic protein aggregates.
• To identify potential interventions for delaying HD pathogenesis by restoring protein homeostasis.

Main Methods:

• Literature review of therapeutic strategies for Huntington's disease.
• Analysis of approaches targeting protein folding, degradation, and aggregate clearance.
• Focus on the role of chaperones, proteasome, and autophagy in managing toxic protein aggregation.

Main Results:

• Abnormal huntingtin protein aggregation impairs cellular quality control, leading to neurodegeneration.
• Enhancing protein degradation pathways (proteasome, autophagy) can help clear toxic aggregates.
• Strategies to improve protein folding and aggregate elimination show potential in mitigating HD progression.

Conclusions:

• Restoring protein homeostasis is a key therapeutic goal for Huntington's disease.
• Targeting protein quality control mechanisms offers a promising avenue for delaying HD pathogenesis.
• Further research into enhancing cellular aggregate clearance is crucial for developing effective HD treatments.